Validación de la determinación de picloram y ácido2,4-diclorofenoxiácetico en muestras ambientales de suelos por cromatografía de líquidos de alta resolución

Se desarrolló y validó una metodología por CLAR que permitió llevar a cabo la determinación de 2,4-D y picloram en muestras de suelo. Los resultados muestran que el método desarrollado es adecuado para los fines previstos ya que cumplen con los criterios de aceptación establecidos. La extracción sólido-líquido asistida por ultrasonido mostro ser eficiente, los parámetros de desempeño obtenidos cumplen con los criterios de aceptación y durante el análisis cromatográfico no se detectaron interferencias provenientes de la matriz. Al aplicar el método muestras ambientales no se encontró evidencia de la presencia de 2,4-D ni de picloram, sin embargo, debe tomarse en cuenta que son compuestos tóxicos y que un inadecuado manejo y una exposición elevada a estos compuestos, puede generar efectos dañinos a la salud.It was developed and validated a HPLC methodology that allowed the determination of 2.4-D and Picloram in soil samples. The results show that the developed method is suitable for the intended purposes as they meet the established acceptance criteria. The solid-fluid extraction assisted by ultrasound showed to be efficient, the performance parameters obtained comply with the criteria of acceptance and during the chromatographic analysis no interferences were detected from the matrix. When applying the environmental samples method, no evidence was found of the presence of 2.4-D or Picloram, however it should be taken into account that they are toxic compounds and that inadequate management and exposure to these compounds can cause harmful health effects

CIBERER : Spanish national network for research on rare diseases: A highly productive collaborative initiative

Altres ajuts: Instituto de Salud Carlos III (ISCIII); Ministerio de Ciencia e Innovación.CIBER (Center for Biomedical Network Research; Centro de Investigación Biomédica En Red) is a public national consortium created in 2006 under the umbrella of the Spanish National Institute of Health Carlos III (ISCIII). This innovative research structure comprises 11 different specific areas dedicated to the main public health priorities in the National Health System. CIBERER, the thematic area of CIBER focused on rare diseases (RDs) currently consists of 75 research groups belonging to universities, research centers, and hospitals of the entire country. CIBERER's mission is to be a center prioritizing and favoring collaboration and cooperation between biomedical and clinical research groups, with special emphasis on the aspects of genetic, molecular, biochemical, and cellular research of RDs. This research is the basis for providing new tools for the diagnosis and therapy of low-prevalence diseases, in line with the International Rare Diseases Research Consortium (IRDiRC) objectives, thus favoring translational research between the scientific environment of the laboratory and the clinical setting of health centers. In this article, we intend to review CIBERER's 15-year journey and summarize the main results obtained in terms of internationalization, scientific production, contributions toward the discovery of new therapies and novel genes associated to diseases, cooperation with patients' associations and many other topics related to RD research

Treatment with tocilizumab or corticosteroids for COVID-19 patients with hyperinflammatory state: a multicentre cohort study (SAM-COVID-19)

Objectives: The objective of this study was to estimate the association between tocilizumab or corticosteroids and the risk of intubation or death in patients with coronavirus disease 19 (COVID-19) with a hyperinflammatory state according to clinical and laboratory parameters. Methods: A cohort study was performed in 60 Spanish hospitals including 778 patients with COVID-19 and clinical and laboratory data indicative of a hyperinflammatory state. Treatment was mainly with tocilizumab, an intermediate-high dose of corticosteroids (IHDC), a pulse dose of corticosteroids (PDC), combination therapy, or no treatment. Primary outcome was intubation or death; follow-up was 21 days. Propensity score-adjusted estimations using Cox regression (logistic regression if needed) were calculated. Propensity scores were used as confounders, matching variables and for the inverse probability of treatment weights (IPTWs). Results: In all, 88, 117, 78 and 151 patients treated with tocilizumab, IHDC, PDC, and combination therapy, respectively, were compared with 344 untreated patients. The primary endpoint occurred in 10 (11.4%), 27 (23.1%), 12 (15.4%), 40 (25.6%) and 69 (21.1%), respectively. The IPTW-based hazard ratios (odds ratio for combination therapy) for the primary endpoint were 0.32 (95%CI 0.22-0.47; p < 0.001) for tocilizumab, 0.82 (0.71-1.30; p 0.82) for IHDC, 0.61 (0.43-0.86; p 0.006) for PDC, and 1.17 (0.86-1.58; p 0.30) for combination therapy. Other applications of the propensity score provided similar results, but were not significant for PDC. Tocilizumab was also associated with lower hazard of death alone in IPTW analysis (0.07; 0.02-0.17; p < 0.001). Conclusions: Tocilizumab might be useful in COVID-19 patients with a hyperinflammatory state and should be prioritized for randomized trials in this situatio

Desarrollo de materiales accesibles y de una metodología basada en perfiles profesionales para la formación de jóvenes con discapacidad intelectual, en la asignatura de Radio del Proyecto Liceo

El objetivo del proyecto es elaborar materiales accesibles para alumnos con discapacidad intelectual de la asignatura de Radio del Proyecto Liceo, y sensibilizar a la comunidad sobre la formación universitaria de jóvenes con discapacidad intelectual.Depto. de Ciencias de la Comunicación AplicadaFac. de Ciencias de la InformaciónFALSEsubmitte